Home > Publications Database > Nanomedicine for prion disease treatment: new insights into the role of dendrimers. > print

001     137108
005     20240321220206.0
024 7 _ |a 10.4161/pri.24431
|2 doi
024 7 _ |a pmid:23764833
|2 pmid
024 7 _ |a pmc:PMC3783103
|2 pmc
024 7 _ |a 1933-6896
|2 ISSN
024 7 _ |a 1933-690X
|2 ISSN
024 7 _ |a altmetric:1561074
|2 altmetric
037 _ _ |a DZNE-2020-03430
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a McCarthy, James M
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Nanomedicine for prion disease treatment: new insights into the role of dendrimers.
260 _ _ |a London [u.a.]
|c 2013
|b Taylor & Francis
264 _ 1 |3 online
|2 Crossref
|b Informa UK Limited
|c 2014-10-27
264 _ 1 |3 print
|2 Crossref
|b Informa UK Limited
|c 2013-05-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1593007628_30277
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Despite their devastating impact, no effective therapeutic yet exists for prion diseases at the symptomatic stage in humans or animals. Progress is hampered by the difficulty in identifying compounds that affect PrP (Sc) and the necessity of any potential therapeutic to gain access to the CNS. Synthetic polymers known as dendrimers are a particularly promising candidate in this area. Studies with cell culture models of prion disease and prion infected brain homogenate have demonstrated that numerous species of dendrimers eliminate PrP (Sc) in a dose and time dependent fashion and specific glycodendrimers are capable of crossing the CNS. However, despite their potential a number of important questions remained unanswered such as what makes an effective dendrimer and how dendrimers eliminate prions intracellularly. In a number of recent studies we have tackled these questions and revealed for the first time that a specific dendrimer can inhibit the intracellular conversion of PrP (C) to PrP (Sc) and that a high density of surface reactive groups is a necessity for dendrimers in vitro anti-prion activity. Understanding how a therapeutic works is a vital component in maximising its activity and these studies therefore represent a significant development in the race to find effective treatments for prion diseases.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Dendrimers
|2 NLM Chemicals
650 _ 7 |a Prions
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Dendrimers: chemistry
|2 MeSH
650 _ 2 |a Dendrimers: pharmacology
|2 MeSH
650 _ 2 |a Dendrimers: therapeutic use
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Nanomedicine
|2 MeSH
650 _ 2 |a Prion Diseases: drug therapy
|2 MeSH
650 _ 2 |a Prion Diseases: metabolism
|2 MeSH
650 _ 2 |a Prions: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Prions: chemistry
|2 MeSH
650 _ 2 |a Prions: metabolism
|2 MeSH
650 _ 2 |a Protein Conformation: drug effects
|2 MeSH
700 1 _ |a Appelhans, Dietmar
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Tatzelt, Jörg
|0 P:(DE-2719)9000396
|b 2
|u dzne
700 1 _ |a Rogers, Mark S
|0 P:(DE-HGF)0
|b 3
773 1 8 |a 10.4161/pri.24431
|b : Informa UK Limited, 2013-05-01
|n 3
|p 198-202
|3 journal-article
|2 Crossref
|t Prion
|v 7
|y 2013
|x 1933-6896
773 _ _ |a 10.4161/pri.24431
|g Vol. 7, no. 3, p. 198 - 202
|0 PERI:(DE-600)2267671-5
|n 3
|q 7:3<198 - 202
|p 198-202
|t Prion
|v 7
|y 2013
|x 1933-6896
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783103
909 C O |o oai:pub.dzne.de:137108
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000396
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|2 G:(DE-HGF)POF3-300
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2013
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PRION : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-2719)5000053
|k Ext AG Tatzelt
|l Ext Neurobiochemistry, LMU
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000053
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1073/pnas.96.25.14529
|9 -- missing cx lookup --
|2 Crossref
|o 10.1073/pnas.96.25.14529
999 C 5 |a 10.1002/chem.200800342
|9 -- missing cx lookup --
|2 Crossref
|o 10.1002/chem.200800342
999 C 5 |a 10.1021/bm100101s
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/bm100101s
999 C 5 |a 10.1128/JVI.75.7.3453-3461.2001
|9 -- missing cx lookup --
|2 Crossref
|o 10.1128/JVI.75.7.3453-3461.2001
999 C 5 |a 10.1099/vir.0.19726-0
|9 -- missing cx lookup --
|2 Crossref
|o 10.1099/vir.0.19726-0
999 C 5 |a 10.1007/s00726-010-0707-z
|9 -- missing cx lookup --
|2 Crossref
|o 10.1007/s00726-010-0707-z
999 C 5 |a 10.1021/bm301165u
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/bm301165u
999 C 5 |a 10.1016/j.colsurfb.2012.02.021
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.colsurfb.2012.02.021
999 C 5 |2 Crossref
|o
999 C 5 |a 10.1371/journal.pone.0055282
|9 -- missing cx lookup --
|2 Crossref
|o 10.1371/journal.pone.0055282
999 C 5 |a 10.1073/pnas.1834432100
|9 -- missing cx lookup --
|2 Crossref
|o 10.1073/pnas.1834432100
999 C 5 |a 10.1002/(SICI)1097-4644(199607)62:1<27::AID-JCB4>3.0.CO;2-3
|9 -- missing cx lookup --
|2 Crossref
|o 10.1002/(SICI)1097-4644(199607)62:1<27::AID-JCB4>3.0.CO;2-3
999 C 5 |a 10.1002/adhm.201200151
|9 -- missing cx lookup --
|2 Crossref
|o 10.1002/adhm.201200151
999 C 5 |a 10.1016/j.biomaterials.2009.11.085
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.biomaterials.2009.11.085
999 C 5 |a 10.1128/JVI.65.12.6597-6603.1991
|9 -- missing cx lookup --
|2 Crossref
|o 10.1128/JVI.65.12.6597-6603.1991
999 C 5 |a 10.1021/bi100370b
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/bi100370b
999 C 5 |a 10.1016/j.febslet.2004.09.073
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.febslet.2004.09.073
999 C 5 |a 10.1016/j.bbrc.2006.04.041
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.bbrc.2006.04.041
999 C 5 |a 10.1016/j.bbrc.2007.09.083
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.bbrc.2007.09.083
999 C 5 |a 10.1101/cshperspect.a006833
|9 -- missing cx lookup --
|2 Crossref
|o 10.1101/cshperspect.a006833
999 C 5 |a 10.1038/emboj.2011.86
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/emboj.2011.86
999 C 5 |a 10.1523/JNEUROSCI.6500-10.2011
|9 -- missing cx lookup --
|2 Crossref
|o 10.1523/JNEUROSCI.6500-10.2011
999 C 5 |a 10.1016/j.tibs.2010.11.001
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.tibs.2010.11.001
999 C 5 |a 10.1021/bm060229s
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/bm060229s
999 C 5 |a 10.1002/mabi.200700049
|9 -- missing cx lookup --
|2 Crossref
|o 10.1002/mabi.200700049
999 C 5 |a 10.1021/mp2005627
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/mp2005627
999 C 5 |a 10.1146/annurev.neuro.24.1.1121
|9 -- missing cx lookup --
|2 Crossref
|o 10.1146/annurev.neuro.24.1.1121
999 C 5 |a 10.1039/c1nj20444k
|9 -- missing cx lookup --
|2 Crossref
|o 10.1039/c1nj20444k

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21